Browse by author
Lookup NU author(s): Dr Bruce Charlton
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Following Horrobin's suggestion of 1986, I argue that offering very large prizes (tens of millions of US dollars, or more) for solving specific therapeutic problems, would be an excellent strategy for promoting the rapid development of effective new treatments. The two mainstream ways of paying for medical research are funding the process with grants or funding the outcome via patent protection. When grants are used to fund the process of research the result tends to be 'pure' science, guided by intrinsic scientific objectives. Practical results, such as useful therapeutic advances, are a by-product. Patent-seeking research, by contrast, is more focused on technology than science. It seeks practical results; and aims to pay for itself (and make a profit) in the tong term by generating a patentable product or procedure. Prize-seeking research is subject to different incentives and applicable to different situations than either process-funded or patent-seeking research. Prize seeking researchers have a strong incentive to solve the specified problem as rapidly as possible, but the problem may be solved using old ideas that are scientifically mundane or unpatentabte technologies and methods. Prizes therefore seem to generate solutions which are incremental extensions, new applications or novel combinations of already-existing technologies. The main use of mega-prizes in medicine would be to accelerate therapeutic progress in stagnant fields of research and to address urgent problems. For example, medical charities focused on specific diseases should consider accumulating their resources until they can offer a mega-prize for solving a clinical problem of special concern to their patients. Prize money should be big enough to pay for the research and development, the evaluation of the new treatment in a clinical trial, and with a large profit left-over to compensate for the intrinsic risk of competing. Sufficiently large amounts of money, and the prestige and publicity derived from winning a mega-prize, could rapidly mobilize research efforts to discover a whole range of scientifically un-glamorous but clinically-useful therapeutic breakthroughs. (c) 2006 Elsevier Ltd. All rights reserved.
Author(s): Charlton BG
Publication type: Editorial
Publication status: Published
Journal: Medical Hypotheses
Year: 2007
Volume: 68
Issue: 1
Pages: 1-3
Print publication date: 01/01/2007
ISSN (print): 0306-9877
ISSN (electronic): 1532-2777
Publisher: Churchill Livingstone
URL: http://dx.doi.org/10.1016/j.mehy.2006.09.025
DOI: 10.1016/j.mehy.2006.09.025
